These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 38193090)

  • 1. The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways.
    Chen Y; Guo DZ; Zhu CL; Ren SC; Sun CY; Wang Y; Wang JF
    Front Immunol; 2023; 14():1323797. PubMed ID: 38193090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway.
    Nakamori Y; Park EJ; Shimaoka M
    Front Immunol; 2020; 11():624279. PubMed ID: 33679715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
    Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
    Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 signaling pathway in sepsis: Does it have a future?
    Chen R; Zhou L
    Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role and application of programmed death protein 1 (PD-1) and its ligand PD-L1 in immune cell dysfunction in sepsis: An update].
    Ding Y; Dai L; Xiang Y; Sun Y; Yu J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Sep; 36(9):843-848. PubMed ID: 32967768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
    Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research advances of myeloid-derived suppressor cells mediated by programmed death-1/programmed death-ligand 1 pathway in sepsis-induced immunosuppression].
    Xu Y; Zang X; Chen W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 Mar; 36(3):332-336. PubMed ID: 38538366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis.
    Hu YM; Hsiung YC; Pai MH; Yeh SL
    JPEN J Parenter Enteral Nutr; 2018 Mar; 42(3):538-549. PubMed ID: 28633555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
    Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS
    Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.
    Li W; Tu J; Liu X; Yang W
    Clin Exp Immunol; 2017 Oct; 190(1):8-18. PubMed ID: 28556912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-L1 peptide improves survival in sepsis.
    Shindo Y; McDonough JS; Chang KC; Ramachandra M; Sasikumar PG; Hotchkiss RS
    J Surg Res; 2017 Feb; 208():33-39. PubMed ID: 27993215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
    Wilson JK; Zhao Y; Singer M; Spencer J; Shankar-Hari M
    Crit Care; 2018 Apr; 22(1):95. PubMed ID: 29661225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphonuclear Myeloid-Derived Cells That Contribute to the Immune Paralysis Are Generated in the Early Phase of Sepsis via PD-1/PD-L1 Pathway.
    Ao X; Yang Y; Okiji T; Azuma M; Nagai S
    Infect Immun; 2021 May; 89(6):. PubMed ID: 33753411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice.
    Zhao ZZ; Wang XL; Xie J; Chen LP; Li Q; Wang XX; Wang JF; Deng XM
    Med Sci Monit; 2021 Jan; 27():e926820. PubMed ID: 33421049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of regulation of PD-1 and PD-L1 expression in sepsis.
    Zhang T; Yu-Jing L; Ma T
    Front Immunol; 2023; 14():1029438. PubMed ID: 36969168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.
    Zhao Y; Jia Y; Li C; Shao R; Fang Y
    Shock; 2019 Mar; 51(3):289-297. PubMed ID: 29702526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
    Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
    Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased percentage of PD-L1
    Jiang W; Li X; Wen M; Liu X; Wang K; Wang Q; Li Y; Zhou M; Liu M; Hu B; Zeng H
    Crit Care; 2020 Oct; 24(1):617. PubMed ID: 33076951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
    Qin W; Hu L; Zhang X; Jiang S; Li J; Zhang Z; Wang X
    Front Immunol; 2019; 10():2298. PubMed ID: 31636634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.